The European life sciences investment landscape sees significant consolidation as Asabys Partners integrates Aliath Bioventures, creating a combined firm with over €468 million assets under management. This strategic merger aims to build a pan-European life sciences investment platform exceeding €1 billion by 2030, enhancing coverage from early-stage tech transfer to growth-stage ventures across biopharma, medtech, and digital health sectors.